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Stereotactic body radiotherapy (SBRT) is a highly confor-mal treatment modality that uses image guidance to allow 
precise delivery of ablative doses of radiation to a target, 
resulting in excellent local control with minimal toxicity.1 
SBRT is increasingly used as an alternative to surgical resec-
tion for patients with early-stage non–small cell lung cancer 
who are considered medically inoperable or refuse surgery.2 In 
addition, there is interest in incorporating SBRT into the treat-
ment of locally advanced non–small cell lung cancer, most 
commonly as a boost to residual disease after conventional 
radiotherapy.3
As the use of SBRT increases, determination of proper 
follow-up of patients is paramount. Acute and late imaging 
changes are common after SBRT, and differentiation between 
residual/recurrent disease and post-SBRT change can be chal-
lenging. Positron emission tomography/computed tomogra-
phy (PET/CT) is a valuable tool in surveillance, as post-SBRT 
change typically does not exhibit fluorodeoxyglucose-avidity 
with standardized uptake values more than 5.4 However, even 
with the aid of PET imaging, misinterpretation of abnormali-
ties is possible. Herein, we report such a case.
CASE PRESENTATION
The patient is a 65-year-old male diagnosed with stage 
IIIA adenocarcinoma, with disease in the left lower lobe and 
station 7. Definitive chemoradiotherapy was recommended, 
with the intention of delivering 6600 cGy in 33 fractions 
to the primary tumor and mediastinum. However, the ini-
tial plan resulted in prohibitive amounts of radiation deliv-
ered to uninvolved lung, with V
20
 of 45%, even with use of 
 intensity-modulated radiotherapy. Thus, the mediastinal vol-
ume was treated with conventional radiotherapy to 6600 cGy 
in 33 fractions (V
20
 = 16.1%) with concurrent cisplatin and eto-
poside. The peripheral tumor was treated with SBRT to 5000 
cGy in five fractions (V
20
 = 7.4%) at the end of conventional 
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FIGURE 1.  Isodose curves for (A) mediastinal field, treated 
to 6600 cGy in 33 fractions; (B) stereotactic body radio-
therapy for the primary tumor, treated to 5000 cGy in five 
fractions; and (C) the summed plan.
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radiotherapy and between cycles of chemotherapy (Fig. 1). 
The summed V
20
 for the hybrid plan was 29.7% although this 
number must be interpreted with caution, as the biologically 
effective dose would certainly have been greater.
Four months later, PET/CT scan showed resolution of 
subcarinal activity. However, the left lower lobe mass was 
noted to have increased in size slightly from pre-SBRT imag-
ing (4.0 versus 2.6 cm in greatest dimension) and SUV max 
(4.3 versus 3.1) (Fig. 2). The area of concern was lateral to the 
area of greatest overlap between the two plans. The appear-
ance on PET/CT was felt to be suggestive of persistent disease 
and thus the patient underwent left lower lobectomy and medi-
astinal lymphadenectomy. Pathologic review of the lobectomy 
specimen revealed organizing pneumonia, with no residual 
tumor in the lobectomy or mediastinal specimens (Fig. 3).
DISCUSSION
Although SBRT results in excellent local control at the 
primary tumor site, failure elsewhere in the lung and in nodal 
volumes remains a concern. Thus, surveillance imaging is 
critical. Interpretation of imaging after SBRT is challenging, 
 however, as post-SBRT CT changes are evident in approxi-
mately 50% of patients within the first 6 months after SBRT, 
often manifesting early as consolidation and  ground-glass 
opacities.4,5
Emerging principles of risk determination are para-
mount in the interpretation of post-SBRT imaging. PET 
imaging provides additional information, as benign processes 
typically demonstrate maximum SUV of less than 5. In addi-
tion, recognition of the fact that growth after 12 months is 
more highly associated with recurrence (5) allows clinicians 
to temporally vary their threshold of concern.
A cautious approach to follow-up, using repeat imaging 
and consideration of the natural history of treatment effects, 
can help patients avoid additional interventions.
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FIGURE 2.  Positron emission 
tomography/computed tomography 
scan at (A) time of diagnosis and (B) 
4 months after radiotherapy.
FIGURE 3.  Pathologic specimens 
from (A) needle aspirate at time of 
diagnosis, demonstrating clusters 
of malignant cells consistent with 
adenocarcinoma (hematoxylin & 
eosin, ×200), and (B) the lobectomy 
specimen, demonstrating organiz-
ing pneumonia, with no evidence of 
residual adenocarcinoma (hematoxy-
lin & eosin, ×100).
